Xilio Therapeutics (XLO) EBIAT (2024 - 2025)
Xilio Therapeutics (XLO) has disclosed EBIAT for 2 consecutive years, with -$11.8 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 9.65% to -$11.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$41.4 million through Dec 2025, up 28.87% year-over-year, with the annual reading at -$42.0 million for FY2025, 27.87% up from the prior year.
- EBIAT hit -$11.8 million in Q4 2025 for Xilio Therapeutics, down from -$1.9 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$1.9 million in Q3 2025 to a low of -$17.2 million in Q1 2024.